In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio Breast Cancer Symposium.

Metastatic cancer refers to cancer that has spread to distant sites in the body. Several types of cancer—including breast cancer—have a tendency to spread to the bone. Bone metastases can lead to serious problems such as fracture and spinal cord compression and may require treatment with surgery or radiation therapy.

Bisphosphonate drugs such as Zometa are commonly used to reduce the risk of complications from bone metastases. Researchers continue, however, to explore new approaches to treatment.

Xgeva is a drug that targets a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break down bone). Xgeva was recently approved for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers.

To directly compare Xgeva to Zometa among breast cancer patients with bone metastases, researchers conducted a Phase III clinical trial among more than 2,000 patients. Study participants were assigned to receive either Xgeva or Zometa. Zometa is given intravenously, and Xgeva is given as a subcutaneous (under-the-skin) injection.

The objective of the study was to determine whether the occurrence of bone complications (“skeletal related events”) differed between the two study groups. The bone complications that were evaluated were fracture, radiation to the bone, surgery to the bone, and spinal cord compression.

  • Patients treated with Xgeva remained free of bone complications for a median of five months longer than patients treated with Zometa.
  • Overall survival was similar in the two groups.
  • Osteonecrosis of the jaw—an uncommon but serious side effect—occurred in 2.5% of patients treated with Xgeva and 1.8% of patients treated with Zometa.

The results of this study suggest that Xgeva is more effective than Zometa at delaying or preventing skeletal complications in breast cancer patients with bone metastases.

Reference: Stopeck A, Martin M, Ritchie D et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Presented at the 33rd annual San Antonio Breast Cancer Symposium, December 8-12, 2010. Abstract P6-14-01.

Copyright © 2016 CancerConsultants. All Rights Reserved.

[ viagra britain | zetia 10mg pills $362.00 | maxaquin 400mg pills $117.00 | effexor 75mg pills $164.00 | lopid 250mg pills $111.00 | lozol 1.5mg pills $129.00 | benemid 500mg pills $169.00 | where can i buy illegal viagra | hytrin 2mg capsules $267.00 | viagra seizures | viagra results | adhd atomoxetine 18mg pills $212.00 | vardenafil 40mg pills $208.00 | lotensin 5mg pills $129.00 | nexium 40mg pills $146.00 | online viagra | zithromax 250mg pills $177.00 | purchasing viagra in canada | buy viagra line | retrovir 100mg pills $96.00 | tadalafil 100mg pills $354.00 | internet viagra pharmacy | fluconazole 150mg pills $223.00 | penegra 100mg pills $327.00 | microzide 25mg pills $174.00 | desyrel 25mg pills $137.00 | gasex 100 tablet bottle $210.00 | herbal viagra | oxytrol 5mg pills $174.00 | minomycin 100mg pills $441.00 | womenra 100mg pills $91.00 | legally purchase viagra | viagra pills | requip 0.25mg pills $229.00 | cialis next day | vigora 50mg pills $122.00 | buy viagra on the internet | paxil 40mg pills $158.00 | viramune 200mg pills $63.00 | vasotec 20mg pills $129.00 | desyrel 50mg pills $117.00 | mirapex 1mg pills $104.00 | sustiva 200mg pills $213.00 | propecia 1mg pills 270 $266.00 | sumycin 250mg pills $126.00 | trazodone 100mg pills $126.00 | trazodone 25mg pills $170.00 | levitra 40mg pills $76.00 | generic viagra usa | cialis from mexico | trazodone 100mg pills $91.00 | tadalafil 50mg pills $182.00 | when was viagra released | generic viagra canadian ]